Abstract
A novel KPC variant, KPC-41, was identified in a Klebsiella pneumoniae clinical isolate from Switzerland. This β-lactamase possessed a 3-amino-acid insertion (Pro-Asn-Lys) located between amino acids 269 and 270 compared to the KPC-3 amino acid sequence. Cloning and expression of the blaKPC-41 gene in Escherichia coli, followed by determination of MIC values and kinetic parameters, showed that KPC-41, compared to those of KPC-3, has an increased affinity to ceftazidime and a decreased sensitivity to avibactam, leading to resistance to ceftazidime-avibactam once produced in K. pneumoniae. Furthermore, KPC-41 exhibited a drastic decrease of its carbapenemase activity. This report highlights that a diversity of KPC variants conferring resistance to ceftazidime-avibactam already circulate in Europe.
Author supplied keywords
Cite
CITATION STYLE
Mueller, L., Masseron, A., Prod’Hom, G., Galperine, T., Greub, G., Poirel, L., & Nordmann, P. (2019). Phenotypic, biochemical, and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrobial Agents and Chemotherapy, 63(12). https://doi.org/10.1128/AAC.01111-19
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.